What is HC Wainwright’s Forecast for CRVS FY2024 Earnings?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Analysts at HC Wainwright issued their FY2024 EPS estimates for Corvus Pharmaceuticals in a research report issued to clients and investors on Thursday, January 2nd. HC Wainwright analyst S. Lee anticipates that the company will post earnings per share of ($0.41) for the year. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ Q1 2025 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.44) EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($0.31) EPS and FY2028 earnings at $0.14 EPS.

A number of other brokerages have also recently commented on CRVS. StockNews.com cut shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH lifted their target price on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Oppenheimer lifted their target price on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Finally, Mizuho upgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Corvus Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $12.38.

Corvus Pharmaceuticals Stock Performance

Shares of Corvus Pharmaceuticals stock opened at $5.83 on Monday. Corvus Pharmaceuticals has a 52-week low of $1.30 and a 52-week high of $10.00. The company has a fifty day moving average of $7.67 and a 200-day moving average of $5.31. The stock has a market capitalization of $374.62 million, a price-to-earnings ratio of -6.27 and a beta of 1.07.

Hedge Funds Weigh In On Corvus Pharmaceuticals

A number of hedge funds have recently modified their holdings of CRVS. Samlyn Capital LLC increased its position in shares of Corvus Pharmaceuticals by 160.7% in the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock valued at $11,144,000 after acquiring an additional 3,774,658 shares during the period. Marshall Wace LLP purchased a new position in shares of Corvus Pharmaceuticals in the second quarter valued at about $136,000. Cubist Systematic Strategies LLC purchased a new position in shares of Corvus Pharmaceuticals in the second quarter valued at about $44,000. Point72 Asset Management L.P. purchased a new position in shares of Corvus Pharmaceuticals in the second quarter valued at about $10,855,000. Finally, Avity Investment Management Inc. increased its position in shares of Corvus Pharmaceuticals by 138.2% in the third quarter. Avity Investment Management Inc. now owns 27,580 shares of the company’s stock valued at $146,000 after acquiring an additional 16,000 shares during the period. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.